Recent Company News

• 07:22 AM ET Feb 24, 2026
  

  Novartis announces new real‑world data reinforce earlier use of Pluvicto before chemotherapy in metastatic castration-resistant prostate cancer (CHF 128.58, +0.60)

• 01:16 AM ET Feb 23, 2026
  

  Novartis presents Rhapsido (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU) (CHF 126.46, 0.00)

• 10:06 AM ET Feb 21, 2026
  

  Johnson & Johnson announces new long-term data from the QUASAR LTE study; TREMFYA (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years ($242.49, 0.00)

• 02:13 AM ET Feb 20, 2026
  

  European macro headlines:

• 10:59 PM ET Feb 19, 2026
  

  Novartis to sell 70.7% stake in Novartis India to consortium (INR 904.00, +73.55)

• 10:06 AM ET Feb 18, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (202 total)

• 01:22 AM ET Feb 18, 2026
  

  Novartis' Phase III RemIND trial of oral remibrutinib in CIndU met the primary endpoint for the three most prevalent types of CIndU (CHF 128.38, 0.00)

• 10:02 AM ET Feb 17, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (210 total)

• 04:19 AM ET Feb 17, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (150 total)

• 01:34 PM ET Feb 13, 2026
  

  FDA approves sNDAs for Leqvio; new patient population (pediatric), new indication (HoFH) for 12 and older (CHF 125.14, 0.00)